Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06741969 · ClinicalTrials.gov registry record · Phase 3
Nipocalimab in Moderate to Severe Sjogren's Disease
A Phase 3 study of Sjogren's Syndrome, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 3
- Development phase
- 655
- Enrollment target
- 20
- Study locations
NCT06741969 is a Phase 3 study of Sjogren's Syndrome that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 655 participants, above the 256-participant average among 20 other Sjogren's Syndrome trials with a reported enrollment target (156% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT06741969, a Phase 3 study of Sjogren's Syndrome, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 655 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the clinical efficacy and safety of nipocalimab in participants with moderate to severe Sjogren's disease (SjD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Nipocalimab
- DRUG Standard of care treatment
Study Locations (20)
California
- Advanced Clinical Research Center - Chula Vista
- Providence Medical Foundation - Fullerton
- Arthritis & Osteoporosis Medical Center - La Palma - La Palma
- NovaMed Research - Monterey Park
- Medvin Clinical Research San Leandro - San Leandro
- Providence Saint John s Health Center - Santa Monica
- Solace Clinical Research California - Tustin
- Inland Rheumatology Clinical Trials Inc. - Upland
Florida
- Clinical Research of West Florida Inc - Clearwater
- UF Health Rheumatology - Jacksonville
- Suncoast Clinical Research - New Port Richey
- Sarasota Arthritis Center - Sarasota
- BioResearch Partner - South Miami
Illinois
- Clinical Investigation Specialists - Clinic of Robert Hozman - Skokie
- Willow Rheumatology and Wellness PLLC - Willowbrook
Colorado
- Denver Arthritis Clinic - Denver
Georgia
- Immunology and Rheumatology Research Associates LLC - Suwanee
Iowa
- University of Iowa Hospital and Clinics - Iowa City
Kansas
- University of Kansas Medical Center - Kansas City
Michigan
- Clinical Research Institute of Michigan, LLC - Saint Clair Shores
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 655 participants |
| Start Date | 2024-12-04 |
| Est. Completion | 2029-08-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06741969
The ClinicalTrials.gov registry entry for NCT06741969 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 655 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 256-participant average among 20 other Sjogren's Syndrome trials with a reported enrollment target (156% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sjogren's Syndrome appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06741969 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT06741969 about?
NCT06741969 is a clinical study titled "Nipocalimab in Moderate to Severe Sjogren's Disease". The purpose of this study is to evaluate the clinical efficacy and safety of nipocalimab in participants with moderate to severe Sjogren's disease (SjD).
What is the current status of trial NCT06741969?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 655 participants. The study started on 2024-12-04. Estimated completion is 2029-08-02.
What conditions does trial NCT06741969 study?
This clinical trial studies the following conditions: Sjogren's Syndrome.
What interventions are being tested in trial NCT06741969?
The interventions under investigation include: Placebo (DRUG), Nipocalimab (DRUG), Standard of care treatment (DRUG).
Who is sponsoring clinical trial NCT06741969?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06741969 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sjogren's Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
ACTIVE NOT RECRUITING · Phase 3
-
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
ACTIVE NOT RECRUITING · Phase 3
-
Rheumatology Diet Study
RECRUITING
-
Creating Health Course Study for People With Rheumatological Conditions
RECRUITING · NA
-
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
RECRUITING · Phase 1
-
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.